Posts Tagged ‘Biotech’
Three Life Sciences Companies Finalist of the Strategis Award
The jury of the Prix Strategis selected five companies, to advance to the final round of the competition. Three of them are Swiss Health Valley projects. Irmos Technologies AG, which develops solutions to extend the lifespan of infrastructure. Neology SA, which offers a clean alternative to diesel. Virtuosis AI, specialized in intelligent vocal biomarkers. Isospec…
Read MoreEPFL Innogrants
Five EPFL-based startups: Alpion CryoSolutions, Eleum, Feedback Intuitive, MOLECL, and NourishAI are the latest recipients of the EPFL Startup Launchpad Innogrant and Innogrant for biotherapeuthics. Each team has secured CHF 100,000 to accelerate the development of their technology. Alpion CryoSolutions Cryo-electron microscopy has transformed biology by allowing researchers to see proteins in extraordinary detail. However, existing technology only…
Read MoreAC Immune and Eli Lilly Sign New Agreement Worth CHF 10 Million
Eli Lilly has handed Vaud-based AC Immune (Switzerland) 10 million Swiss francs ($12.5 million) to expand their Alzheimer’s disease collaboration as a candidate moves closer to the clinic. The U.S. pharma first tapped up AC Immune in a 2018 deal that included an $81 million upfront fee. That pact, which came with up to 1.7 billion francs ($2.1 billion)…
Read MoreOculis Announces European Medicines Agency PRIME Designation for Privosegtor
Oculis Holding AG, based in canton of Vaud and Zug, has received a significant regulatory boost for its neuroprotective candidate Privosegtor, with the European Medicines Agency (EMA) granting the therapy Priority Medicines (PRIME) designation for the treatment of optic neuritis (ON). Optic neuritis is a rare and sight-threatening condition that can occur as a relapse…
Read MoreVenture Leaders Biotech 2026: 10 innovative biotech startups selected for the Boston roadshow
Ten startups, 4 of them from the Swiss Health Valley, have been selected for the 2026 Venture Leaders Biotech programme, which will take them to Boston from May 31st to June 5th as part of the Swiss National Startup Team. During their roadshow, the entrepreneurs will connect with international investors and industry leaders, acquiring expertise…
Read MoreXsensio SA Raises $7 Million in Oversubscribed Series A Funding
Xsensio SA, a Vaud-based high-tech company pioneering continuous biochemical monitoring in near real time, announced the closing of a Series A funding round with an oversubscription of $7 million. The round was led by San Francisco-based venture capital firm WI Harper, with participation from Privilège Ventures, the European Innovation Council and private investors from the…
Read MoreKYLYS AESTHETICS SA Completes its First Clinical Trial
KYLYS AESTHETICS SA, a University of Geneva spinoff and Swiss clinical-stage biotech company developing next-generation regenerative aesthetic medical devices, announces the successful completion of patient injections in its first clinical trial. A total of 55 patients have now been treated as part of this study evaluating the company’s proprietary hyaluronic acid-based injectable technology. This milestone…
Read MoreNewBiologix Announces Publication of Breakthrough HEK293 Cell Line Optimized for High-Quality rAAV Production
NewBiologix S.A., a Swiss Health Valley biotechnology company advancing recombinant adeno-associated virus (rAAV) production through next-generation clonal HEK293 cell line technology, announced publication of peer-reviewed data in Biotechnology Reports (Vol. 49, March 2026).
Read MoreTimeline Partners with Lancôme
Swiss biotech Timeline, born at EPFL Innovation Park, has entered a landmark global partnership with Lancôme, the flagship beauty brand of L’Oréal. The collaboration marks the first worldwide large-scale commercialization of Timeline’s proprietary longevity molecule, Mitopure®, within a global skincare brand. For Timeline, this partnership represents the culmination of nearly two decades of scientific research…
Read MoreSwissmedic approves donanemab for the treatment of early-stage Alzheimer’s disease
The drug, developed by Eli Lilly, slows the progression of the disease, but cannot stop or cure it. Alzheimer Switzerland and Swiss Memory Clinics welcome this decision, but emphasize that many people with Alzheimer’s disease and their families still face significant challenges. On February 4, 2026, the Swiss Agency for Therapeutic Products (Swissmedic) approved the…
Read More